• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: clinical teams outsourcing in Asia now focusing on smaller markets

Report: clinical teams outsourcing in Asia now focusing on smaller markets

July 21, 2011
CenterWatch Staff

A new report says clinical development teams looking for outsourcing opportunities in Asia are turning their attention to smaller emerging markets rather than automatically plumping for established territories such as India and China, according to Pharma-Times.

While India and China previously drew in clinical trials as the two largest members of the BRIC group of countries (Brazil, Russia, India and China), improvements in local expertise and regulatory clarity are bringing other markets such as Malaysia, Hong Kong, Taiwan, Thailand, Singapore, South Korea and the Philippines to the fore, noted the report by Cutting Edge Information, Emerging Markets Clinical Trials: Asia.

Many executives familiar with emerging markets now see the potential benefits of conducting clinical research in Asian countries other than India and China in view of each market's unique qualities, Cutting Edge Information said.

"India and China opened the door for pharma companies to consider focusing on Asia for large parts of their clinical development strategy," said chief operating officer Adam Bianchi. "Now we see a more sophisticated breakdown of country-by-country benefits and costs.”

One large company profiled in the report, for example, has seen clear advantages to running trials in the Philippines. One of its investigational compounds was approved for a new indication on the basis of clinical data in which 30% of patients were enrolled for trials in the Philippines, Cutting Edge Information said.

β€œThe Philippines has a relatively long history and the company found that the country's regulatory environment and medical infrastructure offer a solid base for clinical research,” it added.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing